514 related articles for article (PubMed ID: 16038162)
1. [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff].
Lamers LM; Stalmeier PF; McDonnell J; Krabbe PF; van Busschbach JJ
Ned Tijdschr Geneeskd; 2005 Jul; 149(28):1574-8. PubMed ID: 16038162
[TBL] [Abstract][Full Text] [Related]
2. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
3. Modelling valuations for Eq-5d health states: an alternative model using differences in valuations.
Dolan P; Roberts J
Med Care; 2002 May; 40(5):442-6. PubMed ID: 11961478
[TBL] [Abstract][Full Text] [Related]
4. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
5. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
6. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
Golicki D; Jakubczyk M; Graczyk K; Niewada M
Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
[TBL] [Abstract][Full Text] [Related]
8. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies.
Lamers LM; McDonnell J; Stalmeier PF; Krabbe PF; Busschbach JJ
Health Econ; 2006 Oct; 15(10):1121-32. PubMed ID: 16786549
[TBL] [Abstract][Full Text] [Related]
9. Quality-of-life valuations of advanced breast cancer by New Zealand women.
Milne RJ; Heaton-Brown KH; Hansen P; Thomas D; Harvey V; Cubitt A
Pharmacoeconomics; 2006; 24(3):281-92. PubMed ID: 16519549
[TBL] [Abstract][Full Text] [Related]
10. Inconsistencies in TTO and VAS values for EQ-5D health states.
Lamers LM; Stalmeier PF; Krabbe PF; Busschbach JJ
Med Decis Making; 2006; 26(2):173-81. PubMed ID: 16525171
[TBL] [Abstract][Full Text] [Related]
11. Patient versus general population health state valuations: a case study of non-specific low back pain.
van Dongen JM; van denBerg B; Bekkering GE; van Tulder MW; Ostelo RWJG
Qual Life Res; 2017 Jun; 26(6):1627-1633. PubMed ID: 28155048
[TBL] [Abstract][Full Text] [Related]
12. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
13. Health-related utility values of patients with primary Sjögren's syndrome and its predictors.
Lendrem D; Mitchell S; McMeekin P; Bowman S; Price E; Pease CT; Emery P; Andrews J; Lanyon P; Hunter J; Gupta M; Bombardieri M; Sutcliffe N; Pitzalis C; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Vadivelu S; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Griffiths B; Ng WF;
Ann Rheum Dis; 2014 Jul; 73(7):1362-8. PubMed ID: 23761688
[TBL] [Abstract][Full Text] [Related]
14. Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients.
Kiadaliri AA; Eliasson B; Gerdtham UG
Health Qual Life Outcomes; 2015 Sep; 13():145. PubMed ID: 26374709
[TBL] [Abstract][Full Text] [Related]
15. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
16. Comparison of hypothetical and experienced EQ-5D valuations: relative weights of the five dimensions.
Rand-Hendriksen K; Augestad LA; Kristiansen IS; Stavem K
Qual Life Res; 2012 Aug; 21(6):1005-12. PubMed ID: 21932138
[TBL] [Abstract][Full Text] [Related]
17. A comparison of United States and United Kingdom EQ-5D health states valuations using a nonparametric Bayesian method.
Kharroubi SA; O'Hagan A; Brazier JE
Stat Med; 2010 Jul; 29(15):1622-34. PubMed ID: 20209481
[TBL] [Abstract][Full Text] [Related]
18. Predicting the EuroQol Group's EQ-5D index from CDC's "Healthy Days" in a US sample.
Jia H; Zack MM; Moriarty DG; Fryback DG
Med Decis Making; 2011; 31(1):174-85. PubMed ID: 20375418
[TBL] [Abstract][Full Text] [Related]
19. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
20. Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice.
Yang Z; Luo N; Bonsel G; Busschbach J; Stolk E
Value Health; 2019 Jan; 22(1):38-44. PubMed ID: 30661632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
